<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2013-0-3-13-16</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ВОЗМОЖНОСТЬ РАННЕЙ ДИАГНОСТИКИ СИНДРОМА ШЕГРЕНА КАК ПРЕДШЕСТВЕННИКА ЛИМФОМЫ НА ОСНОВЕ АУТОАНТИТЕЛ (DIAGNOSTIC AUTO-ANTIBODIES APPEAR MANY YEARS BEFORE SYMPTOM ONSET IN LYMPHOMA-PRONE SJOGREN’S SYNDROME)</article-title><trans-title-group xml:lang="en"><trans-title>DIAGNOSTIC AUTO-ANTIBODIES APPEAR MANY YEARS BEFORE SYMPTOM ONSET IN LYMPHOMA-PRONE SJOGREN’S SYNDROME (ВОЗМОЖНОСТЬ РАННЕЙ ДИАГНОСТИКИ СИНДРОМА ШЕГРЕНА КАК ПРЕДШЕСТВЕННИКА ЛИМФОМЫ НА ОСНОВЕ АУТОАНТИТЕЛ)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бредберг</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bredberg</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андерс Бредберг - врач отделения клинический микробиологии, отделение лабораторной медицины, Мальмо</p></bio><bio xml:lang="en"><p>Department of Laboratory Medicine.</p><p>Jan Waldenstroms gata 59, plan 2, Clinical Microbiology, Skane University Hospital, 20502, Malmo, Sweden, tel. +46-40-331350 or +46-40-337203, e-mail: anders.bredberg@med.lu.se</p></bio><email xlink:type="simple">anders.bredberg@med.lu.se</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Университетский госпиталь, Скейн Лундский Университет</institution><country>Швеция</country></aff><aff xml:lang="en"><institution>Lund University, Skane University Hospital</institution><country>Sweden</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>01</day><month>02</month><year>2017</year></pub-date><volume>0</volume><issue>3</issue><fpage>13</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бредберг А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Бредберг А.</copyright-holder><copyright-holder xml:lang="en">Bredberg A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/165">https://www.surgonco.ru/jour/article/view/165</self-uri><abstract><p>Синдром Шегрена (СШ) не является наследственным заболеванием и относительно распространен во взрослом возрасте. Для него характерны повышенная утомляемость, снижение экзокринной железистой функции, продуцирование специфических аутоантител  и фокальная инфильтрация Ви Т-лимфоцитов. Болезнь может  осложняться также злокачественной лимфомой. Большинство пациентов с СШ имеют высокие сывороточные уровни  антиядерных антител (АЯА), а АЯА подтипы  SS-A и SS-B (аутоантитела к РНК -модифицирующим сплайсеомным компонентам) используются в качестве  диагностических маркеров СШ. Антитела к хроматину делают  раковые клетки  более  чувствительными к ДНК-связывающим цитостатическим лекарствам. Это позволяет предположить, что действительно АЯА при СШ может иметь некоторое влияние на клеточные  функции, и, возможно, способствовать возникновению симптомов СШ у пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Sjogren’s syndrome (SS) is a non-hereditary and relatively common disease  with adult onset. It is characterized by extreme tiredness, diminished  exocrine  glandular function, specific auto-antibody production and focal infiltration of B and T lymphocytes. The disease may be also complicated by malignant lymphoma. Most SS patients have high serum levels of anti-nuclear antibodies (ANA), and the ANA subtypes SS-A and SS-B (autoantibodies to RNA-modifying spliceosome components) are used as diagnostic markers of SS. Antibodies to chromatin make  cancer  cells more  sensitive  to DNA-binding  cytostatic drugs  suggests that  indeed  the  ANA in SS may  have  some  influence on  cellular functions, and  perhaps contribute to SS patients’ symptoms.</p><p>A most recent  report from our department has demonstrated that  ANA including SS-A and SS-B are present at high titres in sera obtained from SS patients many years before the onset  of symptoms, and even longer times before the diagnosis was established.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром  Шегрена</kwd><kwd>злокачественная  лимфома</kwd><kwd>антиядерные антитела</kwd><kwd>ДНК</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Sjogren’s syndrome</kwd><kwd>malignant lymphoma</kwd><kwd>anti-nuclear antibodies</kwd><kwd>DNA</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bredberg А. et al. Review. Sjogren’s syndrome and the danger model // Rheumatology. – 2005. Vol. 44. – P. 965–970.</mixed-citation><mixed-citation xml:lang="en">Bredberg А. et al. Review. Sjogren’s syndrome and the danger model // Rheumatology. – 2005. Vol. 44. – P. 965–970.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen et al. Targeting Cancer with a Lupus Autoantibody // Sci Transl Med. 2012. Vol. 4. – P. 142-157.</mixed-citation><mixed-citation xml:lang="en">Hansen et al. Targeting Cancer with a Lupus Autoantibody // Sci Transl Med. 2012. Vol. 4. – P. 142-157.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Henriksson et al. Enhanced DNA-dependent protein kinase activity in Sjogren’s syndrome B cells // Rheumatology. 2004. Vol. 43. – P. 1109–1115.</mixed-citation><mixed-citation xml:lang="en">Henriksson et al. Enhanced DNA-dependent protein kinase activity in Sjogren’s syndrome B cells // Rheumatology. 2004. Vol. 43. – P. 1109–1115.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Henriksson et al. Sjogren’s Syndrome: Lymphoma Predisposition Coupled with a Reduced Frequency of t-translocations in Blood Lymphocytes // Mol Carcinogenesis. (1999 . Vol. 24. P. 226–231.</mixed-citation><mixed-citation xml:lang="en">Henriksson et al. Sjogren’s Syndrome: Lymphoma Predisposition Coupled with a Reduced Frequency of t-translocations in Blood Lymphocytes // Mol Carcinogenesis. (1999 . Vol. 24. P. 226–231.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jonsson et al. Autoantibodies present before symptom onset in primary Sjogren's syndrome // JAMA in press. 2013.</mixed-citation><mixed-citation xml:lang="en">Jonsson et al. Autoantibodies present before symptom onset in primary Sjogren's syndrome // JAMA in press. 2013.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Theander et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors // Ann Rheum Dis. 2006. – Vol. 65. – P. 796-803.</mixed-citation><mixed-citation xml:lang="en">Theander et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors // Ann Rheum Dis. 2006. – Vol. 65. – P. 796-803.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
